MSC Administration for the Management of Type 1 Diabetic Patients
MSC Administration for the Management of Type 1 Diabetic Patients
The purpose of this study is to evaluate whether the administration of multipotent stromal
 cell also referred as to mesenchymal stem cells (MSCs), modified Type 1 Diabetes progression.
Aim: to evaluate whether a single intravenous administration of allogeneic bone
 marrow-derived multipotent stromal cell also referred as to mesenchymal stem cells (MSCs),
 modified endogenous insulin secretion capacity and exogenous insulin requirement in patients
 with Type 1 Diabetes Mellitus.

 Participants: 10, females or males, 18 years or older, diagnosed with Type 1 Diabetes
 Mellitus at most 1 year before enrollment, under exogenous insulin treatment, with pancreatic
 reserve of insulin.

 Intervention: intravenous administration of a single dose (2-3 millions/Kg) of allogeneic
 MSCs.

 Follow up: before and 1, 6, 24 months after MSC administration.
Inclusion Criteria:

 -  differential diagnosis of Type 1 Diabetes

 -  diagnosed performed at most 1 year before enrollment

 -  pancreatic reserve of insulin higher than 0.8 nmol/L/h

 -  good general health status

 -  informed consent of patient

 -  consent of treating physician

 -  proved psychiatric competence to be enrolled in a clinical study

 Exclusion Criteria:

 -  pregnancy

 -  significant comorbidities

 -  HIV, HBV, HCV, HTLV-1, HLTV-2 or VDRL positive